Navigation Links
Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle
Date:10/29/2007

COLUMBUS, Ohio, Oct. 29 /PRNewswire/ -- Ventaira Pharmaceuticals announced today that Battelle, a science and technology development leader, will acquire Ventaira's assets and assist Ventaira in closing its operations. Financial terms of the acquisition were not disclosed.

"We will be working with Battelle to transition our assets. In addition, we will work closely with Battelle to explore employment opportunities for our employees," said Leslie Williams, President and CEO of Ventaira Pharmaceuticals. "I would like to thank all of our investors and employees for their dedication to Ventaira and our technology."

Ventaira's clinical development program and device development work are discontinued effective today, Oct. 29, 2007. Operations at Ventaira are expected to close by Dec. 31, 2007.

About Ventaira

Ventaira is a specialty pharmaceutical company based in Columbus, Ohio that develops a proprietary pulmonary drug delivery technology, Mystic(TM) (Electrohydrodynamic-EHD), and formulation capabilities to deliver drugs more efficiently to and through the lung. EHD is an electronic nebulization process in which an electrical field is applied to a conductive liquid leading to the formation of a soft mist droplet aerosol. Ventaira was spun out from Battelle in 2000.

About Battelle

Battelle provides solutions to some of the world's most important challenges through its three global businesses: National Security, Energy Technology, and Health and Life Sciences. Battelle is the world's largest independent research and development organization with technology contributions that find their way into hundreds of commercial products each year. Conducting $3.8 billion in global R&D annually, Battelle oversees 20,000 employees in more than 120 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy.

Headquartered in Columbus, Ohio, and established in 1929 as a non-profit charitable trust, Battelle focuses on societal and economic impact and actively supports and promotes science and math education.

CONTACT:

Leslie Williams

President and CEO of Ventaira Pharmaceuticals

+1-614-340-2338


'/>"/>
SOURCE Ventaira Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Firmex ... solution that makes it easy for organizations to send and gather large files ... FTP software or email file size limitations. , Using the same market-tested ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked as ... Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who ... perform against those strategies. NetDimensions’ ranking as a Leader due to its strengths ...
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin ... of Clinical Operations. She brings years of expertise in establishing and leading clinical ... foundation as a licensed occupational therapist, through a variety of leadership roles in ...
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with ... It has opened an office in downtown Boston at 745 Atlantic Ave. , ... important to generate evidence on the value they provide, not just to patients, but ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):